Aoife Brennan sold $407k of CLYM
President and CEO at Eliem Therapeutics, Inc.. 30,902 shares at an average of $13.17, traded Jun 29, 2026, filed Jun 30, 2026.
Score components
- +25RoleCEO
- +16Trade size$407k at market
- +10Share of holdings soldSold 26% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-291131, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 27, 2026 | MOption exercise Common Stock10b5-1 | +68,750 | - | - | 118,633 | Jun 30, 2026 |
| Jun 29, 2026 | SOpen-market sale Common Stock10b5-1 | -30,902 | $13.17 | $407k | 87,731 | Jun 30, 2026 |
| Jun 27, 2026 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -68,750 | $0.00 | $0 | 137,500 | Jun 30, 2026 |
Related signals
Other insiders at Eliem Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Eliem Therapeutics, Inc. | Stephen Basil Thomas director | $1.4M 100,000 shares | -18% | |
| 15Weak | Eliem Therapeutics, Inc. | Stephen Basil Thomas director | $350k 50,000 shares | -24% | |
| 23Weak | Eliem Therapeutics, Inc. | Stephen Basil Thomas director | $529k 100,000 shares | -33% | |
| 14Weak | CLYMbuy Eliem Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $25k 7,111 shares | +0% | |
| 39Weak | CLYMbuy Eliem Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $755k 314,561 shares | +10% | |
| 13Weak | Eliem Therapeutics, Inc. | Aoife Brennan President and CEO | $25k 20,618 shares | -30% | |
| 0Weak | Eliem Therapeutics, Inc. | Emily Pimblett SVP, Finance & CAO | $1,540 1,242 shares | -6% | |
| 0Weak | Eliem Therapeutics, Inc. | Emily Pimblett SVP, Finance & CAO | $1,571 1,199 shares | -7% | |
| 0Weak | Eliem Therapeutics, Inc. | Emily Pimblett CHIEF ACCOUNTING OFFICER | $2,495 1,235 shares | -10% | |
| 0Weak | Eliem Therapeutics, Inc. | Emily Pimblett CHIEF ACCOUNTING OFFICER | $9,741 1,191 shares | -14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.